CXCL16 is a putative biomarker for responses of NSCLC patients to Bevacizumab (anti-VEGF) (44), which is consistent with the reduced CXCL16-CXCR6 interactions during cancer progression herein (Figures 6B, C). Here, VEGFA is linked to cancer.